@article{65f18a9978734b5a98e250820a316077,
title = "First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study",
abstract = "Micro-Abstract In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials. {\textcopyright} 2016 Elsevier Inc.",
keywords = "Chromophobe RCC, First-line treatment, nccRCC, Papillary RCC, Pazopanib",
author = "S. Buti and M. Bersanelli and F. Maines and G. Facchini and F. Gelsomino and F. Zustovich and M. Santoni and E. Verri and {De Giorgi}, U. and C. Masini and F. Morelli and M.G. Vitale and T. Sava and G. Prati and C. Librici and A.P. Fraccon and G. Fornarini and M. Maruzzo and F. Leonardi and O. Caffo",
note = "Export Date: 29 August 2017 Correspondence Address: Bersanelli, M.; University Hospital of Parma, Medical Oncology, Via Gramsci 14, Italy; email: bersamel@libero.it",
year = "2017",
doi = "10.1016/j.clgc.2016.12.024",
language = "English",
volume = "15",
pages = "e609--e614",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "4",
}